Harvard Bioscience Announces Third Quarter 2026 Financial Results
HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2026 Financial Results · Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million · Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE)
How this was made
The 30-second read
Why it matters
The earnings release adds fresh financial data for a micro‑cap biotech equipment maker, reaffirming modest growth expectations while highlighting margin compression and a widening loss.
Market read
The report is a primary disclosure for HBIO, offering new numbers but limited broader market relevance.
What to watch
Potential upside from the upcoming Project Viking completion and continued NPI adoption in Q4.
Background
Harvard Bioscience (NASDAQ:HBIO) released its Q3 2026 earnings via an SEC Form 8‑K, detailing revenue, margins, net loss, and guidance for Q4 and full year.
Ticker impact
Harvard Bioscience reaffirmed its full-year 2026 revenue guidance of 3%-5% YoY growth and provided Q4 and full-year adjusted EBITDA guidance.
likely modest pressure as investors weigh higher revenue against widening loss and unchanged guidance
New earnings numbers and guidance are disclosed for the first time; the modest outlook and widening loss suggest limited upside and possible downside risk.
Market effects
Provides a data point for the life‑science equipment sector, indicating steady demand in China but pressure on margins.
Limited impact beyond the niche biotech equipment market.
Low; the release is unlikely to move broader indices.
Counterpoint
The reaffirmed modest guidance may be overly cautious; the 8% revenue growth could support a higher outlook if margin recovery accelerates.
Key entities
- companyHarvard Bioscience Inc.
US‑listed life‑science equipment manufacturer reporting Q3 2026 results.
